Twist Bioscience Corp (TWST) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025 (Q2 Fiscal 2025). Twist Bioscience is a synthetic biology company utilizing silicon-based DNA synthesis technology to manufacture synthetic genes, NGS tools, and biopharma services. The company operates globally with a customer base of approximately 3,562 annually.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $92.8 million | $75.3 million | $181.5 million | $146.8 million |
| Gross Margin | 49.6% | 41.0% | 49.0% | 40.8% |
| Net Loss | $(39.3) million | $(45.5) million | $(70.9) million | $(88.5) million |
| Diluted EPS | $(0.66) | $(0.79) | $(1.19) | $(1.54) |
| Cash & Equivalents | $210.4 million | As of Mar 31, 2025 | ||
| Short-term Investments | $46.7 million | As of Mar 31, 2025 | ||
| Operating Cash Flow | $(13.0) million (Q2 est.) | $(19.4) million (Q2 est.) | $(34.4) million (YTD) | $(42.4) million (YTD) |
Note: Operating cash flow for the quarter is derived from the six-month total less the prior quarter's activity as implied by the MD&A text.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 23% year-over-year (YoY) in Q2 and 24% YoY for the six months ended March 31, 2025. Growth was driven by NGS tools (+$10.4M in Q2) and synthetic genes (+$5.9M in Q2).
- Margin Expansion: Gross margin improved significantly to 49.6% in Q2 from 41.0% in the prior year, attributed to higher revenue volumes spreading fixed costs and process improvements.
- Expense Management: Operating loss narrowed to $41.6 million from $48.9 million. R&D expenses decreased slightly (1%), while SG&A increased 14% primarily due to higher stock-based compensation ($5.3M increase).
- Capital Structure: The company received a $15.0 million upfront payment from XOMA (US) LLC in exchange for future royalty rights, recorded as a liability rather than revenue.
Outlook, Risks, and Unusual Items
- Strategic Divestiture: In a subsequent event (May 2, 2025), the company spun out its DNA data storage assets to Atlas Data Storage, Inc. in exchange for equity, cash, promissory notes, and potential milestones up to $75.0 million.
- Liquidity: Management expects current cash and investments ($257.1 million total) to fund operations for at least one year. Capital expenditure commitments were $4.9 million as of March 31, 2025.
- Legal Proceedings: A securities class action lawsuit (Peters v. Twist Bioscience) remains in the preliminary stage regarding allegations of false statements between 2019 and 2022. A hearing on the motion to dismiss was held in November 2024; the company is awaiting a decision.
- Risk Factors: Risks include geopolitical tensions and new U.S. tariffs affecting supply chains, potential reductions in federal research grants, and the uncertainty of achieving anticipated benefits from the Atlas spin-out.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 23% revenue growth and the specific contribution of the NGS tools segment.
- Margin Sustainability: Assess whether the 49.6% gross margin is maintainable as fixed costs are spread over higher volumes or if it is a temporary anomaly.
- Legal Exposure: Monitor the outcome of the pending motion to dismiss in the securities class action lawsuit.
- Atlas Transaction: Evaluate the valuation and potential upside of the equity stake received in Atlas Data Storage versus the loss of the DNA data storage revenue stream.
- Cash Burn: Track the reduction in operating cash burn (improved from $42.4M to $34.4M YTD) to gauge the path to profitability.